UNSPSC 51152116: Hyoscyamus/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152116 Hyoscyamus/phenobarbital is a Commodity code that in recent state and local procurement activity does not reflect purchases of the pharmaceutical compound itself, but rather refers to acquisitions of naloxone and drug deactivation systems for community health and emergency response. State and local issuing bodies using this code are pursuing naloxone supply contracts and related harm-reduction or overdose-reversal products, typically through counties and state health agencies. Seminole County, Florida and the Texas Health and Human Services Commission represent the jurisdictional mix — county-level health procurement and state agency pharmacy benefit initiatives. The work being solicited includes naloxone unit supply with quarterly delivery schedules, safe drug deactivation systems for community health buildings, and exploratory vendor engagement around direct-to-manufacturer pharmacy benefit models that may encompass prescription fulfillment alternatives outside traditional pharmacy benefit manager and wholesaler channels.

Seminole County released IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, for delivery to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs and self-insured pharmacy contracting models outside traditional group purchasing organization and pharmacy benefit manager arrangements. Recent activity clusters in Florida and Texas, with the Seminole County opportunity representing immediate procurement urgency around naloxone supply and the Texas RFI signaling longer-term state-level pharmacy strategy development. The code shows limited recent activity and a material mismatch between its nominal pharmaceutical compound scope and the actual procurement focus on naloxone distribution systems and pharmacy benefit program restructuring rather than hyoscyamus or phenobarbital products.